Glycomics/Glycobiology Market Analysis

The glycomics/glycobiology market is segmented by product, by application & end-user, out of which, the enzymes segment of product sector is anticipated to hold leading shares in the market on account of consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures. On the contrary, the drug discovery & delivery segment of application sectors is estimated to register a robust growth to the increasing R&D investments in pharmaceutical and biotechnology companies coupled with the rising number of drug discovery research activities in academic research institutes.

Our in-depth analysis of the global market includes the following segments:

Product	·Enzymes Glycosyltransferase Glycosidase ·Instruments Mass Spectrometry Chromatography ·Carbohydrates ·Reagents ·Chemicals
By Application	Drug Discovery & Development Disease Diagnostic Immunology
	Drug Discovery & Development Disease Diagnostic Immunology
End-User	Pharmaceutical & Biotechnology Industry Research Laboratories Academic Others

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of glycomics/glycobiology is estimated at USD 1.89 billion.

Glycomics/Glycobiology Market size was over USD 1.71 billion in 2022 and is anticipated to cross USD 8.57 billion by 2035, growing at more than 13.2% CAGR during the forecast period i.e., between 2024-2036.

North America industry is expected to hold largest revenue share by 2036, attributed to increasing investments in glycomics/glycobiology research, presence of all key players, along with the rising R&D investments in pharmaceutical companies for drug discovery.

The major players in the market are Merck KGaA, Bruker Corporation, Thermo Fisher Scientific, Inc., Shimadzu Corporation, RayBiotech, New England Biolabs Inc., Bio-Techne Corporation, Chemily Glycoscience, Dextra Laboratories Ltd., and others.

Glycomics/Glycobiology Market Analysis